{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T23:36:28Z","timestamp":1790552188050,"version":"4.1.0"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,4,14]],"date-time":"2018-04-14T00:00:00Z","timestamp":1523664000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s00277-018-3324-7","type":"journal-article","created":{"date-parts":[[2018,4,14]],"date-time":"2018-04-14T12:22:49Z","timestamp":1523708569000},"page":"1727-1729","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Re-treatment versus extended treatment strategy of systemic bevacizumab in hereditary hemorrhagic telangiectasia: which is better?"],"prefix":"10.1007","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8216-3457","authenticated-orcid":false,"given":"Narendranath","family":"Epperla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Kleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Karafin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Foy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,14]]},"reference":[{"issue":"2","key":"3324_CR1","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1097\/00004836-200302000-00013","volume":"36","author":"AM Larson","year":"2003","unstructured":"Larson AM (2003) Liver disease in hereditary hemorrhagic telangiectasia. J Clin Gastroenterol 36(2):149\u2013158","journal-title":"J Clin Gastroenterol"},{"issue":"8","key":"3324_CR2","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1136\/thx.54.8.714","volume":"54","author":"CL Shovlin","year":"1999","unstructured":"Shovlin CL, Letarte M (1999) Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations: issues in clinical management and review of pathogenic mechanisms. Thorax 54(8):714\u2013729","journal-title":"Thorax"},{"issue":"927","key":"3324_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1136\/pmj.79.927.18","volume":"79","author":"ME Begbie","year":"2003","unstructured":"Begbie ME, Wallace GM, Shovlin CL (2003) Hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu syndrome): a view from the 21st century. Postgrad Med J 79(927):18\u201324","journal-title":"Postgrad Med J"},{"issue":"6","key":"3324_CR4","first-page":"818","volume":"90","author":"H Sadick","year":"2005","unstructured":"Sadick H, Riedel F, Naim R, Goessler U, Hormann K, Hafner M et al (2005) Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression. Haematologica 90(6):818\u2013828","journal-title":"Haematologica"},{"issue":"20","key":"3324_CR5","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1056\/NEJMc0901421","volume":"360","author":"P Bose","year":"2009","unstructured":"Bose P, Holter JL, Selby GB (2009) Bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 360(20):2143\u20132144","journal-title":"N Engl J Med"},{"issue":"1","key":"3324_CR6","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3121\/cmr.2013.1205","volume":"13","author":"N Epperla","year":"2015","unstructured":"Epperla N, Hocking W (2015) Blessing for the bleeder: bevacizumab in hereditary hemorrhagic telangiectasia. Clin Med Res 13(1):32\u201335","journal-title":"Clin Med Res"},{"issue":"6","key":"3324_CR7","doi-asserted-by":"publisher","first-page":"E313","DOI":"10.1002\/ajh.24367","volume":"91","author":"N Epperla","year":"2016","unstructured":"Epperla N, Kapke JT, Karafin M, Friedman KD, Foy P (2016) Effect of systemic bevacizumab in severe hereditary hemorrhagic telangiectasia associated with bleeding. Am J Hematol 91(6):E313\u2013E314","journal-title":"Am J Hematol"},{"issue":"9","key":"3324_CR8","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1001\/jama.2012.250","volume":"307","author":"S Dupuis-Girod","year":"2012","unstructured":"Dupuis-Girod S, Ginon I, Saurin JC, Marion D, Guillot E, Decullier E et al (2012) Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA 307(9):948\u2013955","journal-title":"JAMA"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-018-3324-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3324-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3324-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,13]],"date-time":"2019-04-13T19:29:34Z","timestamp":1555183774000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-018-3324-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,14]]},"references-count":8,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["3324"],"URL":"https:\/\/doi.org\/10.1007\/s00277-018-3324-7","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,14]]},"assertion":[{"value":"31 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}